Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Nationwide Estimates of Viral Load Suppression and Acquired HIV Drug Resistance in Cameroon.

Tchouwa GF, Eymard-Duvernay S, Cournil A, Lamare N, Serrano L, Butel C, Bertagnolio S, Mpoudi-Ngole E, Raizes E, Aghokeng AF; EHRICA Study Group.

EClinicalMedicine. 2018 Jul 4;1:21-27. doi: 10.1016/j.eclinm.2018.06.005. eCollection 2018 Jul.

2.

HIV Drug Resistance in Resource-limited Countries: Threat for HIV Elimination.

Ngo-Giang-Huong N, Aghokeng AF.

EClinicalMedicine. 2019 Apr 1;9:3-4. doi: 10.1016/j.eclinm.2019.03.013. eCollection 2019 Mar. No abstract available.

3.

Prevalence of pretreatment HIV drug resistance in West African and Southeast Asian countries.

Ngo-Giang-Huong N, Huynh THK, Dagnra AY, Toni TD, Maiga AI, Kania D, Eymard-Duvernay S, Peeters M, Soulie C, Peytavin G, Rekacewicz C, Chaix ML, Aghokeng AF; ANRS 12333 Study Group .

J Antimicrob Chemother. 2019 Feb 1;74(2):462-467. doi: 10.1093/jac/dky443.

4.

Prevalence of pretreatment HIV drug resistance in Cameroon following a nationally representative WHO survey.

Tchouwa GF, Eymard-Duvernay S, Cournil A, Lamare N, Serrano L, Butel C, Bertagnolio S, Mpoudi-Ngole E, Raizes E, Aghokeng AF; Members of the EHRICA Study Group .

J Antimicrob Chemother. 2018 Sep 1;73(9):2468-2474. doi: 10.1093/jac/dky221.

PMID:
29931063
5.

Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.

Ciaffi L, Koulla-Shiro S, Sawadogo AB, Ndour CT, Eymard-Duvernay S, Mbouyap PR, Ayangma L, Zoungrana J, Gueye NFN, Diallo M, Izard S, Bado G, Kane CT, Aghokeng AF, Peeters M, Girard PM, Le Moing V, Reynes J, Delaporte E; MOBIDIP study group.

Lancet HIV. 2017 Sep;4(9):e384-e392. doi: 10.1016/S2352-3018(17)30069-3. Epub 2017 May 28.

PMID:
28566227
6.

HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing.

Rhee SY, Jordan MR, Raizes E, Chua A, Parkin N, Kantor R, Van Zyl GU, Mukui I, Hosseinipour MC, Frenkel LM, Ndembi N, Hamers RL, Rinke de Wit TF, Wallis CL, Gupta RK, Fokam J, Zeh C, Schapiro JM, Carmona S, Katzenstein D, Tang M, Aghokeng AF, De Oliveira T, Wensing AM, Gallant JE, Wainberg MA, Richman DD, Fitzgibbon JE, Schito M, Bertagnolio S, Yang C, Shafer RW.

PLoS One. 2015 Dec 30;10(12):e0145772. doi: 10.1371/journal.pone.0145772. eCollection 2015.

7.

HIV-1 group O infection in Cameroon from 2006 to 2013: Prevalence, genetic diversity, evolution and public health challenges.

Villabona-Arenas CJ, Domyeum J, Mouacha F, Butel C, Delaporte E, Peeters M, Mpoudi-Ngole E, Aghokeng AF.

Infect Genet Evol. 2015 Dec;36:210-216. doi: 10.1016/j.meegid.2015.09.006. Epub 2015 Sep 11.

8.

Gender Differences in Adherence and Response to Antiretroviral Treatment in the Stratall Trial in Rural District Hospitals in Cameroon.

Boullé C, Kouanfack C, Laborde-Balen G, Boyer S, Aghokeng AF, Carrieri MP, Kazé S, Dontsop M, Mben JM, Koulla-Shiro S, Peytavin G, Spire B, Delaporte E, Laurent C; Stratall ANRS 12110ESTHER Study Group.

J Acquir Immune Defic Syndr. 2015 Jul 1;69(3):355-64. doi: 10.1097/QAI.0000000000000604.

PMID:
26181708
9.

Correction: Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis.

Rhee SY, Blanco JL, Jordan MR, Taylor J, Lemey P, Varghese V, Hamers RL, Bertagnolio S, de Wit TF, Aghokeng AF, Albert J, Avi R, Avila-Rios S, Bessong PO, Brooks JI, Boucher CA, Brumme ZL, Busch MP, Bussmann H, Chaix ML, Chin BS, D'Aquin TT, De Gascun CF, Derache A, Descamps D, Deshpande AK, Djoko CF, Eshleman SH, Fleury H, Frange P, Fujisaki S, Harrigan PR, Hattori J, Holguin A, Hunt GM, Ichimura H, Kaleebu P, Katzenstein D, Kiertiburanakul S, Kim JH, Kim SS, Li Y, Lutsar I, Morris L, Ndembi N, Kee PN, Paranjape RS, Peeters M, Poljak M, Price MA, Ragonnet-Cronin ML, Reyes-Terán G, Rolland M, Sirivichayakul S, Smith DM, Soares MA, Soriano VV, Ssemwanga D, Stanojevic M, Stefani MA, Sugiura W, Sungkanuparph S, Tanuri A, Tee KK, Truong HM, van de Vijver DA, Vidal N, Yang C, Yang R, Yebra G, Ioannidis JP, Vandamme AM, Shafer RW.

PLoS Med. 2015 Jun 1;12(6):e1001845. doi: 10.1371/journal.pmed.1001845. eCollection 2015 Jun. No abstract available.

10.

Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis.

Rhee SY, Blanco JL, Jordan MR, Taylor J, Lemey P, Varghese V, Hamers RL, Bertagnolio S, Rinke de Wit TF, Aghokeng AF, Albert J, Avi R, Avila-Rios S, Bessong PO, Brooks JI, Boucher CA, Brumme ZL, Busch MP, Bussmann H, Chaix ML, Chin BS, D'Aquin TT, De Gascun CF, Derache A, Descamps D, Deshpande AK, Djoko CF, Eshleman SH, Fleury H, Frange P, Fujisaki S, Harrigan PR, Hattori J, Holguin A, Hunt GM, Ichimura H, Kaleebu P, Katzenstein D, Kiertiburanakul S, Kim JH, Kim SS, Li Y, Lutsar I, Morris L, Ndembi N, Ng KP, Paranjape RS, Peeters M, Poljak M, Price MA, Ragonnet-Cronin ML, Reyes-Terán G, Rolland M, Sirivichayakul S, Smith DM, Soares MA, Soriano VV, Ssemwanga D, Stanojevic M, Stefani MA, Sugiura W, Sungkanuparph S, Tanuri A, Tee KK, Truong HM, van de Vijver DA, Vidal N, Yang C, Yang R, Yebra G, Ioannidis JP, Vandamme AM, Shafer RW.

PLoS Med. 2015 Apr 7;12(4):e1001810. doi: 10.1371/journal.pmed.1001810. eCollection 2015 Apr. Erratum in: PLoS Med. 2015 Jun;12(6):e1001845.

11.

Challenges of antiretroviral treatment monitoring in rural and remote-access regions in Africa.

Taieb F, Aghokeng AF, Eymard-Duvernay S, Chia JE, Einterz E, Mpoudi-Ngole E, Peeters M, Molina JM, Delaporte E.

AIDS Res Hum Retroviruses. 2014 Jul;30(7):623-5. doi: 10.1089/AID.2014.0035. Epub 2014 Apr 14. No abstract available.

PMID:
24645979
12.

Field evaluation of dried blood spots for routine HIV-1 viral load and drug resistance monitoring in patients receiving antiretroviral therapy in Africa and Asia.

Monleau M, Aghokeng AF, Eymard-Duvernay S, Dagnra A, Kania D, Ngo-Giang-Huong N, Touré-Kane C, Truong LX, Chaix ML, Delaporte E, Ayouba A, Peeters M; ANRS 12235 Study Group.

J Clin Microbiol. 2014 Feb;52(2):578-86. doi: 10.1128/JCM.02860-13. Epub 2013 Dec 11.

13.

Extraordinary heterogeneity of virological outcomes in patients receiving highly antiretroviral therapy and monitored with the World Health Organization public health approach in sub-saharan Africa and southeast Asia.

Aghokeng AF, Monleau M, Eymard-Duvernay S, Dagnra A, Kania D, Ngo-Giang-Huong N, Toni TD, Touré-Kane C, Truong LX, Delaporte E, Chaix ML, Peeters M, Ayouba A; ANRS 12186 Study Group.

Clin Infect Dis. 2014 Jan;58(1):99-109. doi: 10.1093/cid/cit627. Epub 2013 Sep 27.

PMID:
24076968
14.

Population-based monitoring of emerging HIV-1 drug resistance on antiretroviral therapy and associated factors in a sentinel site in Cameroon: low levels of resistance but poor programmatic performance.

Billong SC, Fokam J, Aghokeng AF, Milenge P, Kembou E, Abessouguie I, Meva'a-Onglene FB, Bissek AC, Colizzi V, Mpoudi EN, Elat JB, Shiro KS.

PLoS One. 2013 Aug 26;8(8):e72680. doi: 10.1371/journal.pone.0072680. eCollection 2013.

15.

Prediction of HIV drug resistance based on virologic, immunologic, clinical, and/or adherence criteria in the Stratall ANRS 12110/ESTHER trial in Cameroon.

Boullé C, Kouanfack C, Laborde-Balen G, Aghokeng AF, Boyer S, Carrieri MP, Kazé S, Mben JM, Dontsop M, Spire B, Peeters M, Mpoudi-Ngolé E, Delaporte E, Laurent C; Stratall ANRS 12110/ESTHER Study Group.

Clin Infect Dis. 2013 Aug;57(4):604-7. doi: 10.1093/cid/cit323. Epub 2013 May 10.

PMID:
23667264
16.

Susceptibility to transmitting HIV in patients initiating antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER Trial).

Ndziessi G, Cohen J, Kouanfack C, Marcellin F, Carrieri MP, Laborde-Balen G, Protopopescu C, Aghokeng AF, Moatti JP, Spire B, Delaporte E, Laurent C, Boyer S; Stratall ANRS 12110/ESTHER Study Group.

PLoS One. 2013 Apr 30;8(4):e62611. doi: 10.1371/journal.pone.0062611. Print 2013. Erratum in: PLoS One. 2013;8(7). doi:10.1371/annotation/8963fb4d-336a-4607-8fd9-c3404414ff9c. Carierri, Maria Patrizia [corrected to Carrieri, Maria Patrizia].

17.

Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis.

Boyer S, March L, Kouanfack C, Laborde-Balen G, Marino P, Aghokeng AF, Mpoudi-Ngole E, Koulla-Shiro S, Delaporte E, Carrieri MP, Spire B, Laurent C, Moatti JP; Stratall ANRS 12110/ESTHER Study Group.

Lancet Infect Dis. 2013 Jul;13(7):577-86. doi: 10.1016/S1473-3099(13)70073-2. Epub 2013 Apr 18.

PMID:
23602084
18.

Declining trends in early warning indicators for HIV drug resistance in Cameroon from 2008-2010: lessons and challenges for low-resource settings.

Fokam J, Billong SC, Bissek AC, Kembou E, Milenge P, Abessouguie I, Nkwescheu AS, Tsomo Z, Aghokeng AF, Ngute GD, Ndumbe PM, Colizzi V, Elat JB.

BMC Public Health. 2013 Apr 8;13:308. doi: 10.1186/1471-2458-13-308.

19.

Virological outcome and patterns of HIV-1 drug resistance in patients with 36 months' antiretroviral therapy experience in Cameroon.

Aghokeng AF, Kouanfack C, Eymard-Duvernay S, Butel C, Edoul GE, Laurent C, Koulla-Shiro S, Delaporte E, Mpoudi-Ngole E, Peeters M.

J Int AIDS Soc. 2013 Jan 31;16:18004. doi: 10.7448/IAS.16.1.18004.

20.

Time patterns of adherence and long-term virological response to non-nucleoside reverse transcriptase inhibitor regimens in the Stratall ANRS 12110/ESTHER trial in Cameroon.

Meresse M, Carrieri MP, Laurent C, Kouanfack C, Protopopescu C, Blanche J, Cohen J, Laborde-Balen G, Aghokeng AF, Spire B, Moatti JP, Delaporte E, Boyer S; Stratall ANRS 12110/ESTHER Study Group.

Antivir Ther. 2013;18(1):29-37. doi: 10.3851/IMP2535. Epub 2013 Jan 29.

PMID:
23358393
21.

Task shifting HIV care in rural district hospitals in Cameroon: evidence of comparable antiretroviral treatment-related outcomes between nurses and physicians in the Stratall ANRS/ESTHER trial.

Boullé C, Kouanfack C, Laborde-Balen G, Carrieri MP, Dontsop M, Boyer S, Aghokeng AF, Spire B, Koulla-Shiro S, Delaporte E, Laurent C; Stratall ANRSESTHER Study Group.

J Acquir Immune Defic Syndr. 2013 Apr 15;62(5):569-76. doi: 10.1097/QAI.0b013e318285f7b6.

PMID:
23337365
22.

Successful integrase inhibitor-based highly active antiretroviral therapy for a multidrug-class-resistant HIV type 1 group O-infected patient in Cameroon.

Aghokeng AF, Kouanfack C, Peeters M, Mpoudi-Ngole E, Delaporte E.

AIDS Res Hum Retroviruses. 2013 Jan;29(1):1-3. doi: 10.1089/AID.2012.0196. Epub 2012 Sep 11. No abstract available.

PMID:
22889147
23.

Early warning indicators for HIV drug resistance in Cameroon during the year 2010.

Billong SC, Fokam J, Nkwescheu AS, Kembou E, Milenge P, Tsomo Z, Dion GN, Aghokeng AF, Mpoudi EN, Ndumbe PM, Colizzi V, Elat Nfetam JB.

PLoS One. 2012;7(5):e36777. doi: 10.1371/journal.pone.0036777. Epub 2012 May 17.

24.

Failure to detect simian immunodeficiency virus infection in a large Cameroonian cohort with high non-human primate exposure.

Djoko CF, Wolfe ND, Aghokeng AF, Lebreton M, Liegeois F, Tamoufe U, Schneider BS, Ortiz N, Mbacham WF, Carr JK, Rimoin AW, Fair JN, Pike BL, Mpoudi-Ngole E, Delaporte E, Burke DS, Peeters M.

Ecohealth. 2012 Mar;9(1):17-23. doi: 10.1007/s10393-012-0751-0. Epub 2012 Mar 7.

PMID:
22395958
25.

Lamivudine-resistant HBV infection in HIV-positive patients receiving antiretroviral therapy in a public routine clinic in Cameroon.

Kouanfack C, Aghokeng AF, Mondain AM, Bourgeois A, Kenfack A, Mpoudi-Ngolé E, Ducos J, Delaporte E, Laurent C.

Antivir Ther. 2012;17(2):321-6. doi: 10.3851/IMP1911. Epub 2011 Sep 23.

PMID:
22290198
26.

Drug resistance mutations of HIV type 1 non-B viruses to integrase inhibitors in treatment-naive patients from sub-saharan countries and discordant interpretations.

Monleau M, Aghokeng AF, Nkano BA, Chaix ML, Peeters M; AC11/AC12 ANRS Working Group.

AIDS Res Hum Retroviruses. 2012 Sep;28(9):1157-60.

PMID:
22236055
27.

Scale-up of antiretroviral treatment in sub-Saharan Africa is accompanied by increasing HIV-1 drug resistance mutations in drug-naive patients.

Aghokeng AF, Kouanfack C, Laurent C, Ebong E, Atem-Tambe A, Butel C, Montavon C, Mpoudi-Ngole E, Delaporte E, Peeters M.

AIDS. 2011 Nov 13;25(17):2183-8. doi: 10.1097/QAD.0b013e32834bbbe9.

PMID:
21860346
28.

Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial.

Laurent C, Kouanfack C, Laborde-Balen G, Aghokeng AF, Mbougua JB, Boyer S, Carrieri MP, Mben JM, Dontsop M, Kazé S, Molinari N, Bourgeois A, Mpoudi-Ngolé E, Spire B, Koulla-Shiro S, Delaporte E; Stratall ANRS 12110/ESTHER study group.

Lancet Infect Dis. 2011 Nov;11(11):825-33. doi: 10.1016/S1473-3099(11)70168-2. Epub 2011 Aug 8.

PMID:
21831714
29.

High failure rate of the ViroSeq HIV-1 genotyping system for drug resistance testing in Cameroon, a country with broad HIV-1 genetic diversity.

Aghokeng AF, Mpoudi-Ngole E, Chia JE, Edoul EM, Delaporte E, Peeters M.

J Clin Microbiol. 2011 Apr;49(4):1635-41. doi: 10.1128/JCM.01478-10. Epub 2011 Jan 26.

30.

Characterization of a new simian immunodeficiency virus strain in a naturally infected Pan troglodytes troglodytes chimpanzee with AIDS related symptoms.

Etienne L, Nerrienet E, LeBreton M, Bibila GT, Foupouapouognigni Y, Rousset D, Nana A, Djoko CF, Tamoufe U, Aghokeng AF, Mpoudi-Ngole E, Delaporte E, Peeters M, Wolfe ND, Ayouba A.

Retrovirology. 2011 Jan 13;8:4. doi: 10.1186/1742-4690-8-4.

31.

Genetic diversity among human immunodeficiency virus-1 non-B subtypes in viral load and drug resistance assays.

Peeters M, Aghokeng AF, Delaporte E.

Clin Microbiol Infect. 2010 Oct;16(10):1525-31. doi: 10.1111/j.1469-0691.2010.03300.x. Review.

32.

Genetic diversity of simian lentivirus in wild De Brazza's monkeys (Cercopithecus neglectus) in Equatorial Africa.

Aghokeng AF, Ayouba A, Ahuka S, Liegoies F, Mbala P, Muyembe JJ, Mpoudi-Ngole E, Delaporte E, Peeters M.

J Gen Virol. 2010 Jul;91(Pt 7):1810-6. doi: 10.1099/vir.0.021048-0. Epub 2010 Mar 10.

33.

WHO clinical criteria-based initiation of antiretroviral therapy: lessons from rural district hospitals in Cameroon with regard to 2009 revised WHO recommendations.

Kouanfack C, Laborde-Balen G, Aghokeng AF, Bourgeois A, Dontsop M, Mben JM, Kazé S, Mpoudi-Ngolé E, Koulla-Shiro S, Delaporte E, Laurent C; Stratall ANRS 12110/ESTHER Study Group.

Trop Med Int Health. 2010 May;15(5):580-3. doi: 10.1111/j.1365-3156.2010.02495.x. Epub 2010 Mar 1.

34.

Inaccurate diagnosis of HIV-1 group M and O is a key challenge for ongoing universal access to antiretroviral treatment and HIV prevention in Cameroon.

Aghokeng AF, Mpoudi-Ngole E, Dimodi H, Atem-Tambe A, Tongo M, Butel C, Delaporte E, Peeters M.

PLoS One. 2009 Nov 6;4(11):e7702. doi: 10.1371/journal.pone.0007702.

35.

Low prevalence of HIV type 1 drug resistance mutations in untreated, recently infected patients from Burkina Faso, Côte d'Ivoire, Senegal, Thailand, and Vietnam: the ANRS 12134 study.

Ayouba A, Lien TT, Nouhin J, Vergne L, Aghokeng AF, Ngo-Giang-Huong N, Diop H, Kane CT, Valéa D, Rouet F, Joulia-Ekaza D, Toni TD, Nerrienet E, Ngole EM, Delaporte E, Costagliola D, Peeters M, Chaix ML.

AIDS Res Hum Retroviruses. 2009 Nov;25(11):1193-6. doi: 10.1089/aid.2009.0142.

PMID:
19886834
36.

Evaluation of transmitted HIV drug resistance among recently-infected antenatal clinic attendees in four Central African countries.

Aghokeng AF, Vergne L, Mpoudi-Ngole E, Mbangue M, Deoudje N, Mokondji E, Nambei WS, Peyou-Ndi MM, Moka JJ, Delaporte E, Peeters M.

Antivir Ther. 2009;14(3):401-11.

PMID:
19474474
37.

Extensive survey on the prevalence and genetic diversity of SIVs in primate bushmeat provides insights into risks for potential new cross-species transmissions.

Aghokeng AF, Ayouba A, Mpoudi-Ngole E, Loul S, Liegeois F, Delaporte E, Peeters M.

Infect Genet Evol. 2010 Apr;10(3):386-96. doi: 10.1016/j.meegid.2009.04.014. Epub 2009 Apr 23.

38.

Full-length sequence analysis of SIVmus in wild populations of mustached monkeys (Cercopithecus cephus) from Cameroon provides evidence for two co-circulating SIVmus lineages.

Aghokeng AF, Bailes E, Loul S, Courgnaud V, Mpoudi-Ngolle E, Sharp PM, Delaporte E, Peeters M.

Virology. 2007 Apr 10;360(2):407-18. Epub 2006 Dec 6.

39.

Widely varying SIV prevalence rates in naturally infected primate species from Cameroon.

Aghokeng AF, Liu W, Bibollet-Ruche F, Loul S, Mpoudi-Ngole E, Laurent C, Mwenda JM, Langat DK, Chege GK, McClure HM, Delaporte E, Shaw GM, Hahn BH, Peeters M.

Virology. 2006 Feb 5;345(1):174-89. Epub 2005 Oct 27.

40.

Simian immunodeficiency viruses (SIVs) in Africa.

Aghokeng AF, Peeters M.

J Neurovirol. 2005;11 Suppl 1:27-32. Review. No abstract available.

PMID:
15960238
41.

Enfuvirtide binding domain is highly conserved in non-B HIV type 1 strains from Cameroon, West Central Africa.

Aghokeng AF, Ewane L, Awazi B, Nanfack A, Delaporte E, Zekeng L, Peeters M.

AIDS Res Hum Retroviruses. 2005 May;21(5):430-3.

PMID:
15929708
42.

Evaluation of four simple/rapid assays and two fourth-generation ELISAs for the identification of HIV infection on a serum panel representing the HIV-1 group M genetic diversity in Cameroon.

Aghokeng AF, Ewane L, Awazi B, Nanfack A, Delaporte E, Peeters M, Zekeng L.

J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1632-40.

PMID:
15577422

Supplemental Content

Loading ...
Support Center